TP53 and urinary bladder carcinoma: Gene analysis using DepMap further revealed that although the TP53 mutation confers resistance of bladder cancer cells to cisplatin, it has no significant effect on the sensitivity to gemcitabine or pterostilbene (Figure 2B), suggesting that pterostilbene may have an effect on bladder cancer cells despite the presence of the TP53 genotype.